World ADC Event Series reposted this
Senior Vice President, Head R&D Biologics Engineering and Oncology Targeted Discovery, AstraZeneca
I was delighted to have been able to participate in a stimulating panel discussing the growth and success of antibody drug conjugates (ADCs) and what is coming in ADC innovation, with some of the brightest minds in the field. When I first started attending World ADC Event Series years ago, there were just a few people attending. Now that the field of ADCs has matured, it has attracted a lot of attention, and it was great to see so many people in attendance. My AstraZeneca colleagues also presented at this World ADC, with Frank Comer discussing how we are advancing next-generation radioconjugates built on the pioneering work of Fusion Pharmaceuticals to unlock new tumor types and redefine radiotherapy in oncology, and Jay Harper sharing reflections on ADC combination development in 2023 and 2024 with a look to the future of ADC combinations. I’m proud of how we continue to build our ADC and RC portfolio at AstraZeneca. We presented our first clinical ADC data from our internal development platform earlier this year, but this is only the beginning. Our ultimate aim is to transform traditional chemotherapy and radiotherapy regimens. Read more of my thoughts on the potential of ADCs and RCs: https://lnkd.in/es4kYHH5
It was great to meet you and hear your thoughts about ADCs and about the need for better clinical imaging similar to radioconjugates. I agree that we need to see where the therapeutic reaches the most to optimize the treatment measures and modalities to match the disease.
Amazing
Hearty congratulations Puja Sapra, I am sure it must have been a great event!!
Business Development | Learn fast. Build trust. Execute. | I help startups go from 0 to 1.
2moIt was great to hear your insights at the conference and your blog post nicely captures the complexities of ADC payload selection, especially in addressing tumor heterogeneity and resistance. I’m curious about how AstraZeneca approaches predicting resistance mechanisms in preclinical stages since it's such a critical area for durable responses. In our work Turbine, we've found in silico modeling particularly useful for exploring ADC payloads, resistance factors, and combinations. Would love to hear your thoughts on how you see these approaches evolving.